Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies January 18, 2026
Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies November 9, 2025
ViroCell Biologics and AvenCell Therapeutics to accelerate development of novel allogeneic CAR-T therapies for blood cancers August 5, 2025
Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform July 29, 2025
FDA approves label updates for Breyanzi and Abecma to reduce certain patient monitoring requirements and removes the Risk Evaluation and Mitigation Strategy (REMS) programs July 1, 2025
DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies April 30, 2025
Moffitt Cancer Center Announces Strategic Collaboration With Galapagos To Transform CAR T Manufacturing in the Southeast April 30, 2025
First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 February 11, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors January 15, 2025
CRLs submitted to request lifting the clinical holds for zevorcabtagene autoleucel, satricabtagene autoleucel and CT071 October 15, 2024
Positive Interim Ph 1 Results for P-BCMA-ALLO1 with High ORR in Heavily Pretreated RRMM Patients Reported October 8, 2024
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies July 1, 2024
Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Ph 1/2 Clinical Trial of MB-106 Announced June 25, 2024
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies May 14, 2024
Dosing Initiated in Second Cohort of Ovarian Cancer FSHR-targeting CER-T Clinical Trial February 26, 2024
IND Applications approved by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors February 26, 2024
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics February 26, 2024
